MediumCardiologyHeart failure with reduced ejection fractionca-mccqe1ca-rcpsc-im
A 59-year-old man with heart failure with reduced ejection fraction (LVEF 30%) is on maximally tolerated ACE inhibitor, evidence-based beta-blocker and mineralocorticoid receptor antagonist. He remains NYHA class II with resting blood pressure 118/72 mm Hg and potassium 4.4 mmol/L. According to contemporary Canadian guidelines, which additional therapy has the greatest prognostic benefit?